News - Unibest Industrial Co., Ltd.

Blogs

Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Lenacapavir: Market Analysis of the First-in-Class Capsid Inhibitor
2023-10-13

In August 2022, Gilead announced that the European Commission (EC) has granted marketing authorization for Sunlenca (Lenacapavir), an innovative treatment for adults with multi-drug resistant HIV infection. The treatment works in combination with other antiretroviral(s) when it isn't Read More
Understanding the Mechanism of Action of Lenacapavir: A Novel HIV Capsid Inhibitor
2023-10-12

Lenacapavir (Sunlenca, GS-6207) is a groundbreaking HIV drug developed by Gilead Sciences as a component of long-acting antiretroviral therapy. This first-in-class capsid inhibitor was approved by the EC in August 2022 and by the FDA in December 2022. Displaying impressive results in clinical trials Read More
A Breif Drug Development Analysis of Antiretrovirals
2023-09-26

Antiretroviral drugs have evolved significantly over time, with new drugs continuously being developed. The analysis below provides some insights into the development timeline, the focus on drug classes, and the use of drugs in combination formulations.Evolution of Drug ClassesThe following timeline Read More
Tautomers: Interconversion of Isomers
2023-09-22

Tautomerization refers to the equilibrium system between two isomers, which can be interconverted by moving both double bonds and protons. It exemplifies a special kind of isomerism. A common example of isomerism is the ketone-enol tautomerization, such as the conversion between acetone Read More
HIV, a Typical Retrovirus Life Cycle
2023-09-19

HIV, or human immunodeficiency virus, is a retrovirus that infects and destroys the immune system's CD4+ T cells, leading to acquired immunodeficiency syndrome (AIDS). But how does this tiny virus manage to invade cells and cause so much damage? Here's an overview. Read More
Trilaciclib, The First-in-Class Myeoprotection: Market, Advantages, and Competitions
2023-09-15

In recent years, the concept of myeloprotection—protecting bone marrow from the damaging effects of chemotherapy—has emerged as a crucial component in cancer therapy. In the face of this evolving landscape, G1 Therapeutics' trilaciclib (marketed as COSELA®) stands out. Trilaciclib is the first thera Read More
Pralsetinib and NSCLC
2023-09-14

Compounds with CAS RN 2097133-17-8, CAS RN 2778223-52-0 and CAS RN 35277-02-2 can be used to synthesize Read More
Targeting CDK4/6 in Cancer Drug Development: Challenges and Opportunities
2023-09-14

The cell cycle is tightly regulated to ensure proper cell division and growth. Cyclin-dependent kinases (CDKs) play a crucial role in controlling cell cycle progression. In particular, CDK4 and CDK6 partner with D-type cyclins during the G1 phase to phosphorylate and inactivate the retinoblastoma (R Read More
Advancements in Pralsetinib Production: The New Intermediates on The Block
2023-09-04

IntroductionPralsetinib, an innovative cancer-fighting drug, has been making significant strides in targeted oncology therapy—specifically against non-small cell lung cancer (NSCLC) with RET gene alterations. Pralsetinib's remarkable efficacy and ability to provide targeted treatment for cancer make Read More